Table 2.

The overall and dose-dependent incidence of ipilimumab-related pituitary enlargement, anterior pituitary hormone deficiencies, and hyponatremia

OverallIpilimumab (3 mg/kg)Ipilimumab (10 mg/kg)
MaleFemaleTotalTotalTotal
N = 19N = 6N = 25N = 17N = 8
Pituitary enlargement
 Yes10 (53)5 (83)15 (60)10 (59)5 (63)
 No9 (47)1 (17)10 (40)7 (41)3 (37)
Secondary AI
 Yes18 (95)4 (67)22 (88)15 (88)7 (88)
 No1 (5)2 (33)3 (12)2 (12)1 (12)
Secondary hypothyroidism
 Yes18 (95)4 (67)22 (88)15 (88)7 (88)
 No1 (5)2 (33)3 (12)2 (12)1 (12)
Secondary hypogonadism
 Yes15 (79)0 (0)15 (60)10 (59)5 (63)
 No2 (11)3 (50)5 (20)4 (24)1 (13)
 Not measured2 (11)3 (50)5 (20)3 (18)2 (25)
Low IGFI
 Yes3 (60)0 (0)3 (12)1 (33)2 (50)
 No2 (40)2 (33)4 (16)2 (67)2 (50)
 Not measured14 (74)4 (67)18 (72)14 (82)4 (50)
Low prolactin
 Yes4 (21)0 (0)4 (16)2 (12)2 (25)
 No4 (21)1 (17)5 (20)2 (12)3 (38)
 Not measured11 (58)5 (83)16 (64)13 (76)3 (38)
Hyponatremia
 Yes12 (63)2 (33)14 (56)10 (59)3 (38)
 No7 (37)4 (67)11 (44)7 (41)5 (62)

NOTE: Values are summarized as N (%).The incidence of each anterior pituitary hormone deficiency was calculated on the basis of gender and ipilimumab dose, taking into account the number of patients with ipilimumab-related hypophysitis in whom the measure was assessed. The incidence is shown as both the number affected and as a percentage.

Abbreviation: AI, adrenal insufficiency.